Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 4/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277409 | 0.82 | MAPK13 (0.52) | MAPK14MAPK13PIK3CGNR4A2CDK8 | |
| SCHEMBL3278461 | 0.76 | CDK8 (0.40) | MAPK14MAPK13FGFR1FGFR3FYN | |
| SCHEMBL3279744 | 0.76 | PDK2 (0.46) | MAPK14MAPK13 | |
| SCHEMBL3277807 | 0.75 | MAPK13 (0.34) | MAPK14MAPK13RAF1 | |
| SCHEMBL380037 | 0.75 | MAPK13 (0.69) | MAPK14MAPK13RAF1 | |
| SCHEMBL380013 | 0.72 | MAPK13 (0.46) | MAPK14MAPK13RAF1 | |
| SCHEMBL3025015 | 0.70 | FGFR3 (0.49) | FGFR1FGFR3FYNPIK3CGNR4A2 | |
| SCHEMBL13702375 | 0.69 | HDAC8 (0.68) | FYNPIK3CGNR4A2CDK8CRBN | |
| SCHEMBL380899 | 0.69 | MAPK14 (0.56) | MAPK14MAPK13RAF1 | |
| SCHEMBL379882 | 0.68 | MAPK13 (0.78) | MAPK14MAPK13RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | MAPK14 39/4885MAPK13 37/4885FGFR1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.